About
Overview
Management
Board of Directors
Pipeline
Overview
Pegozafermin (BIO89-100)
FGF21
NASH
SHTG
Clinical Trials
Scientific Publications
Investors
Corporate Profile
Press Releases
Events & Presentations
Corporate Governance
Stock Information
Financials & Filings
Investor Resources
Careers
Overview
Values
Benefits
Open Jobs
Contact
Corporate profile
Press releases
Events and presentations
Scientific publications
Corporate governance
Stock information
Financials & filings
Analyst coverage
Investor resources
A clinical-stage biopharmaceutical company developing a differentiated FGF21 for NASH and SHTG
NASDAQ: XXXX
$18.00
+0.3 (+1.69%)
Copyright West LLC. Minimum 15 minutes delayed.
Press Releases
09/25/2019
89bio Announces Dosing of First Patients in NASH Study and Issuance of Composition of Matter Patent
08/08/2019
89bio Initiates Phase 1b/2a Proof of Concept Clinical Trial of Investigational Therapy BIO89-100 for the Treatment of NASH
05/22/2019
89bio Reports Positive Top-line Data from Phase 1 Single-Ascending Dose Clinical Trial of BIO89-100, an Investigational Medicine for NASH
View All
Investor Inquiries
Investor@89bio.com
General Information
Info@89bio.com
Shareholder tools
Print page
RSS feeds
Share page
E-mail alerts
